Drug
Zalifrelimab clinical trials
Also written AGEN1884.
- studies test it
- 10
- open now
- 2
- in phase 3
- 0
- first study started
- 2016
Keep track of what changes. Save the zalifrelimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Agenus Inc. (5) · University of Colorado, Denver (1) · Nelum Corp (1) · Ann & Robert H Lurie Children's Hospital of Chicago (1) · ImmunoGenesis (1) · The University of Texas Health Science Center at San Antonio (1)
Often tested with
Tested in the same studies.
Balstilimab (6) · Gemcitabine (2) · Botensilimab (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Hedgehog Inhibitor NLM-001 (1) · TH 302 (1) · Cisplatin (1)
Studies
Open first, then newest update. How each study uses zalifrelimab is read from its arms, and is right about nine times in ten.
Testing it · 10
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGRecruitingPhase 1Ann & Robert H Lurie Children's Hospital of ChicagoNCT04943848Written as Zalifrelimab
- A Study of Evofosfamide in Combination with Zalifrelimab and BalstilimabRecruitingPhase 1/2ImmunoGenesisNCT06782555Written as Zalifrelimab
- A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)CompletedPhase 1/2Agenus Inc.NCT03495882Written as Zalifrelimab
- Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue SarcomasActive, not recruitingPhase 2University of Colorado, DenverNCT04028063Written as Zalifrelimab
- RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerTerminatedPhase 2Agenus Inc.NCT03894215Written as AGEN1884
- AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent TherapyCompletedPhase 1/2Agenus Inc.NCT02694822Written as Zalifrelimab
- Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic CancerActive, not recruitingPhase 1/2Nelum CorpNCT04827953Written as Zalifrelimab
- AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder CancerTerminatedPhase 2The University of Texas Health Science Center at San AntonioNCT04430036Written as AGEN1884
- A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerWithdrawnPhase 2Agenus Inc.NCT05033132Written as Balstilimab + Zalifrelimab
- AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaWithdrawnPhase 2Agenus Inc.NCT04607200Written as AGEN1884
Given in every arm · 1 — zalifrelimab is usual care beside what is tested
Codes
What other systems call zalifrelimab · ClinicalTrials.gg INT016555
- UNII (FDA) FE7L22H028ZALIFRELIMABOne source FDA
- NCI Thesaurus C126113ZalifrelimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FE7L22H028 | ZALIFRELIMAB | One source FDA |
| NCI Thesaurus | C126113 | Zalifrelimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.